



## COMPANY OVERVIEW

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

## RECENT NEWS

### **MANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published in Peer-Reviewed Journal Experimental Neurobiology**

Jul 9 2018, 8:00 AM EDT

### **MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model**

Jun 11 2018, 7:00 AM EDT

### **Amarantus Provides Update on Elto Pharma Capital Formation Plan**

Jun 7 2018, 9:08 AM EDT

## STOCK OVERVIEW

Symbol	AMBS
Exchange	OTCPink
Shares OS	68,272,000
Market Cap	\$2.53M
Last Price	<b>\$0.037</b>
52-Week Range	<b>\$0.01 - \$0.2085</b>
Fiscal Year End	<b>December 31</b>

## INVESTOR RELATIONS

American Capital Ventures, Inc.  
Howard Gostfrand  
President  
T: 305-918-7000  
F: 305-468-6165  
[hg@amcapventures.com](mailto:hg@amcapventures.com)

## MANAGEMENT TEAM

### **Gerald E. Commissiong**

President & Chief Executive Officer

### **Barney Monte**

Interim Chief Operating Officer and Chief Financial Officer

### **Brian E. Harvey, MD, PhD**

Chief Regulatory Advisor

### **Elise Brownell, Ph.D.**

Senior Vice President of Operations and Project Management

### **John W. Commissiong, PhD**

Chief Scientific Officer

### **Paula Trzepacz, MD**

Chief Medical Advisor to Elto Pharma

### **Dr. Richard Kagan**

Chief Medical Advisor to Cutanogen Corporation

### **Michael T. Ropacki, PhD**

Chief Medical Advisor - Alzheimer's Blood Diagnostic LymPro Test®

## AMARANTUS BIOSCIENCE HOLDINGS, INC.

110 Wall Street  
New York, NY 10005  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.